PR Newswire
17 May 2023, 04:30 GMT+10
LAUSANNE, Switzerland, May 17, 2023 /PRNewswire/ -- Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow's standards of care to cure cancer and infectious diseases, today announced the start of its open-label Phase 1/2 study evaluating Debio 0123, a brain-penetrant and highly selective WEE1 inhibitor, in combination with temozolomide (TMZ) in patients with recurrent or progressive glioblastoma and in combination with TMZ/RT (SOC) in newly diagnosed patients. The initial phase of this study aims to define the recommended phase 2 doses of Debio 0123.
GBM is among the most aggressive and common lethal tumors of the central nervous system. This disease represents a major cause of morbidity and mortality affecting more than 13,000 Americans and causing the death of about 10,000 patients in 2022 1. If left untreated, in some cases GBM can lead to the patient's death in approximately 3 months. This type of cancer tends to occur more often in adults between 65-75 years of age. Throughout the continuum of this devastating disease, patients face serious quality of life issues including motor deficits, personality changes, cognitive deficits, language disorders (aphasia) or visual field defects. The disease's poor prognosis constitutes a serious public health concern.
With its Debio 0123 WEE1 inhibitor, Debiopharm is seeking to meet the urgent need for novel treatment interventions to improve clinical outcomes and quality of life for patients suffering from newly diagnosed or recurrent GBM. In cancer cells, DDR pathways are often upregulated due to genomic instability, elevating the chances of resistance to DNA-damaging therapies. Therefore, blocking DNA repair pathways through inhibition of essential kinases such as WEE1 might contribute to increase the cancer's vulnerability to standard of care therapies. Moreover, preclinical results presented at AACR 2023 have shown that Debio 0123 successfully crosses the blood brain barrier and inhibits tumor growth. Furthermore, the in vivo combination of Debio 0123 with TMZ demonstrated significantly increased antitumor activity.
"I am very excited to witness the development of a new generation of brain penetrant drugs. Having drugs like this allows us to explore novel treatments for brain tumors, which remains an ongoing challenge." Dr. Jordi Rodon Ahnert, MD, PhD, MD Anderson Cancer Center, Houston, Texas.
"The combination of Debio 0123 with temozolomide is promising. Treatment with Debio 0123 to inhibit WEE1 has the advantage of selectively impacting tumor cells, which, due to the increasing replication stress during the S-phase, become more reliant on the proper functioning of the G2-M checkpoint. Debio 0123 acting at both S-phase and G2-M checkpoint can thus make GBM cells more vulnerable to DNA-damaging agents like temozolomide" expressed Dr. Victor Rodriguez-Freixinos, Associate Medical Direction in Oncology at Debiopharm.
"Due to its physiological and structural properties, the blood brain barrier represents a unique challenge for drug delivery and a massive obstacle to patient's care. Thus, Debio 0123 brain permeability represents an important source of hope to patients suffering from brain cancers" stated Dr. Patrick Roth, University Hospital Zrich.
About Glioblastoma
Glioblastomas are fast-growing and aggressive brain tumors that can arise de novo or evolve from lower grade gliomas. GBM may be asymptomatic until it reaches a significant size. Aside from diagnostic challenges, nearly all GBM recur, and effective treatment options are limited. The widely accepted SOC for patients with newly diagnosed GBMs consists of surgical resection, followed by radiation therapy with concurrent TMZ. Despite treatment, nearly all GBM recur, the 5-year survival rate is still only 6.8% 1 and treatment options are very limited.
About Debio 0123
Debio 0123 is a brain-penetrant, highly selective WEE1 kinase inhibitor. WEE1 is a key regulator of the G2/M and S phase checkpoints, activated in response to DNA damage, allowing cells to repair their DNA before resuming their cell cycle. WEE1 inhibition, particularly in combination with DNA damaging agents, induces an overload of DNA breaks. In conjunction with abrogation of other checkpoints such as G1, the compound pushes the cells through cycle without DNA repair, promoting mitotic catastrophe and inducing apoptosis of cancer cells. Currently in research for solid tumors in monotherapy and combination, Debio 0123 is being developed to respond to high unmet needs of patients living with the burden of difficult-to-treat cancers.
About DNA-Damage Repair (DDR)
When cells have damaged DNA, they need to undergo a repair process called DDR to be able to survive. Cancer cells use their hyperactive DDR response to divide and grow uncontrollably, which promotes cancer expansion. Inhibition of DDR, particularly in combination with other anticancer agents, induces an overall arrest in the uncontrollable cancer cell cycle. This ultimately activates a self-destruction program in cancer cells. DDR inhibitors such as Debiopharm's WEE1 and USP1 inhibitors, are being tested in clinical and preclinical studies.
Debiopharm's commitment to patients
Debiopharm aims to develop innovative therapies that target high unmet medical needs in oncology and bacterial infections. Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds and technologies for in-licensing, clinically demonstrate their safety and efficacy, and then hands stewardship to large pharmaceutical commercialization partners to maximize patient access globally.
For more information, please visit www.debiopharm.com
We are on Twitter. Follow us @DebiopharmNews at http://twitter.com/DebiopharmNews
Debiopharm Contact
Dawn Bonine
Head of Communications
[email protected]
Tel: +41 (0)21 321 01 11
References
1 National Brain Tumor Society. About Glioblastoma. https://doi.org/10.1038/s41419-022-05271-0
Get a daily dose of Vietnam Tribune news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Vietnam Tribune.
More InformationWASHINGTON, D.C.: President Donald Trump says the United States could soon reach a trade deal with India. He believes this deal would...
Nearly three months after a devastating earthquake struck Myanmar, the country remains trapped in a deepening crisis, compounded by...
Chinese FM urges China, France to uphold multilateralism, rules of free trade China and France should champion multilateralism and...
Birmingham [UK], July 6 (ANI): Indian bowling coach Morne Morkel hailed skipper Shubman Gill after a record-breaking outing at Birmingham,...
Bengaluru (Karnataka) [India], July 5 (ANI): Following his win at the inaugural NC Classic at Bengaluru, India's world champion and...
New Delhi [India], July 5 (ANI): India's batting mainstay Virat Kohli had unstinting praise in store for Test captain Shubman Gill,...
MADRID, Spain: Liverpool footballer Diogo Jota and his younger brother, André Silva, have died in a car accident in Spain. Spanish...
LONDON, U.K.: An unrelenting heatwave sweeping across Europe has pushed early summer temperatures to historic highs, triggering deadly...
President Donald Trump's plans to build a space-based Golden Dome missile defense shield have drawn immediate criticism from China,...
NEW YORK CITY, New York: Paramount has agreed to pay US$16 million to settle a lawsuit brought by U.S. President Donald Trump over...
LONDON, U.K.: British Prime Minister Keir Starmer won a vote in Parliament this week to move ahead with changes to the country's welfare...
WASHINGTON, D.C.: President Donald Trump will meet Israeli Prime Minister Benjamin Netanyahu at the White House on Monday. President...